Evidence map›Paper›PMID 42230492›Full record

ArticleBulletin of experimental biology and medicine2026

Effect of Modified Nucleotides on the Immunogenicity of the H1N1 Influenza mRNA Vaccine.

S I Krasnikova, S V Sharabrin, D N Kisakov, M B Borgoyakova, E V Starostina, E V Tigeeva, K P Makarova, V A Yakovlev, K I Ivanova, A P Rudometov and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

S I KrasnikovaState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia. sveta.krasnikova2000@yandex.ru.
S V SharabrinState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
D N KisakovState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
M B BorgoyakovaState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
E V StarostinaState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
E V TigeevaState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
K P MakarovaState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
V A YakovlevState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
K I IvanovaState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
A P RudometovState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
A A IlyichevState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
L I KarpenkoState Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed the effect of modified nucleotides on the immunogenicity of mRNA vaccine encoding hemagglutinin of the influenza A/California/04/09(H1N1) pdm09 virus. Seven mRNA-H1 variants including the following modified bases in different ratios were obtained: N1-methylpseudouridine (m1Ψ), pseudouridine (Ψ), N6-methyladenine (m6A), and 5-methylcytidine (m5C). The efficacy of the resulting mRNA vaccines was assessed by their ability to induce specific antibodies and T-cell response in immunized mice. Virus-neutralizing activity was recorded in groups of animals immunized with mRNAs containing 100% m1Ψ, 100% Ψ, and 100% U. It was shown that mRNAs including 100% m1Ψ or 100% Ψ were more effective than other mRNA variants and induced potent B- and T-cell immune response.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza VaccinesRNA, MessengerAnimalsAntibodies, ViralCytidineFemaleMiceMice, Inbred BALB CPseudouridineT-Lymphocytes5-methylcytidineAntibodies, ViralCytidineInfluenza VaccinesPseudouridineRNA, Messenger5-methylcytidinemodified nucleotidesN1-methyl-pseudouridineN6-methyladeninepseudouridine

Identifiers

PMID42230492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.